Somnomed Ltd
ASX:SOM
Somnomed Ltd
Cost of Revenue
Somnomed Ltd
Cost of Revenue Peer Comparison
Competitors Analysis
Latest Figures & CAGR of Competitors
| Company | Cost of Revenue | CAGR 3Y | CAGR 5Y | CAGR 10Y | ||
|---|---|---|---|---|---|---|
|
|
Somnomed Ltd
ASX:SOM
|
Cost of Revenue
-AU$40.1m
|
CAGR 3-Years
-17%
|
CAGR 5-Years
-9%
|
CAGR 10-Years
-9%
|
|
|
C
|
Cyclopharm Ltd
ASX:CYC
|
Cost of Revenue
-AU$9.6m
|
CAGR 3-Years
-24%
|
CAGR 5-Years
-27%
|
CAGR 10-Years
-11%
|
|
|
Cochlear Ltd
ASX:COH
|
Cost of Revenue
-AU$560m
|
CAGR 3-Years
-12%
|
CAGR 5-Years
-9%
|
CAGR 10-Years
-8%
|
|
|
Optiscan Imaging Ltd
ASX:OIL
|
Cost of Revenue
-AU$667.3k
|
CAGR 3-Years
21%
|
CAGR 5-Years
6%
|
CAGR 10-Years
-30%
|
|
|
Austco Healthcare Ltd
ASX:AHC
|
Cost of Revenue
-AU$27.5m
|
CAGR 3-Years
-24%
|
CAGR 5-Years
-10%
|
CAGR 10-Years
N/A
|
|
|
EMvision Medical Devices Ltd
ASX:EMV
|
Cost of Revenue
N/A
|
CAGR 3-Years
N/A
|
CAGR 5-Years
N/A
|
CAGR 10-Years
N/A
|
|
Somnomed Ltd
Glance View
SomnoMed Ltd. produces and sells oral treatment of sleep related disorder devices. The company is headquartered in Sydney, New South Wales. The company went IPO on 2004-08-27. The firm provides treatment solutions for sleep-related breathing disorders, including obstructive sleep apnea, snoring, and bruxism. SomnoMed has developed the SomnoDent, a collection of oral devices. SomnoDent includes two product line, such as signature line and standard line. Its signature line products include Herbst Advance Elite, Fusion, Flex and Classic, and standard line products include Herbst Advance, Air/Air+, Morning Repositioner and Alpha. SomnoMed has developed the SomnoBrux, a custom fit acrylic occlusal splint. SomnoBrux product includes Michigan. SomnoMed has developed the SomGauge, is an autoclavable instrument, which can be used to construct accurate and reliable bite records.
See Also
What is Somnomed Ltd's Cost of Revenue?
Cost of Revenue
-40.1m
AUD
Based on the financial report for Dec 31, 2024, Somnomed Ltd's Cost of Revenue amounts to -40.1m AUD.
What is Somnomed Ltd's Cost of Revenue growth rate?
Cost of Revenue CAGR 10Y
-9%
Over the last year, the Cost of Revenue growth was -18%. The average annual Cost of Revenue growth rates for Somnomed Ltd have been -17% over the past three years , -9% over the past five years , and -9% over the past ten years .
You don't have any saved screeners yet